Meeting
2023 ASCO Annual Meeting
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).
Authors
Mitchell Elliott
Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
Mitchell Elliott , Jesús Fuentes Antrás , Philippe Echelard , Nicholas Meti , Alisa Nguyen , Michelle Liu , Carolina Sanabria Salas , Christopher Gareth Smith , Moira Katherine Rushton , Lillian L. Siu , Hal K. Berman , Philippe L. Bedard , David W. Cescon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT05388149
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS620)
DOI
10.1200/JCO.2023.41.16_suppl.TPS620
Abstract #
TPS620
Poster Bd #
447b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
First Author: Nicholas Patrick McAndrew
Poster
2023 ASCO Annual Meeting
Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.
First Author: Po-Han Lin